AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283
in treating young patients with relapsed or refractory acute leukemia.